{
    "id": 20075,
    "cites": 42,
    "cited_by": 2,
    "reference": [
        "Acemoglu, D., A. Finkelstein, and M. J. Notowidigdo (2009): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Income and Health Spending: Evidence from Oil Price Shocks,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, MIT.",
        "Baker, S. R., N. Bloom, and S. J. Davis (2013): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Measuring Economic Policy Uncertainty,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, Stanford University.",
        "Barro, R. J. (1996): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health and Economic Growth,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, Harvard University.",
        "Barro, R. J., and T. Jin (2011): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093On the Size Distribution of Macroeconomic Disasters,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Econometrica, 79(5), 1567\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1589.",
        "Belo, F., V. Gala, and J. Li (2013): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Government Spending, Political Cycles and the Cross Section of Stock Returns,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Financial Economics, 107, 305\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c324.",
        "Brogaard, J., and A. L. Detzel (2013): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Asset Pricing Implications of Government Economic Policy Uncertainty,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, University of Washington.",
        "Caves, R. E., M. D. Whinston, and M. A. Hurwitz (1991): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Brookings Papers: Microeconomics, pp. 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c66.",
        "Cutler, D. M. (1995): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Technology, Health Costs, and the NIH,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, Harvard University.",
        "DiMasi, J. A., and R. W. Hansen (2003): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Price of Innovation: New Estimates of Drug Development Costs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics, 22, 151\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c185.",
        "Egan, M., and T. Philipson (2013): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093International Health Economics,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper 19280.",
        "Ellison, S. F., and W. P. Mullin (2001): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Gradual Incorporation of Information: Pharmaceutical Stocks and the Evolution of President Clinton\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2s Health Care Reform,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Law and Economics, 34, 89\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c129.",
        "(1997): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Industry Costs of Equity,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Financial Economics, 43, 153\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c193.",
        "Finkelstein, A., E. F. Luttmer, and M. J. Notowidigdo (2008): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093What Good Is Wealth Without Health? The Effect of Health on the Marginal Utility of Consumption,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, MIT.",
        "Gabaix, X. (2012): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Variable Rare Disasters: An Exactly Solved Framework for Ten Puzzles in Macro-Finance,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Quarterly Journal of Economics, 127(2), 645\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c700.",
        "Geanakoplos, J., and S. P. Zeldes (2011): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Market Value of Social Security,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, Yale University.",
        "Gerdtham, U.-G., and B. Jonsson (2000): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093International comparisons of health expenditure: Theory, data and econometric analysis,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Handbook of Health Economics, 1, 11\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c53.",
        "Golec, J. H., S. Hegde, and J. Vernon (2010): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceutical R&D Spending and Threats of Price Regulation,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Financial and Quantitative Analysis, 45, 239\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c264.",
        "Grossman, S. J., and Z. Zhou (1993): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Optimal Investment Strategies for Controlling Drawdowns, \u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Mathematical Finance, 3, 241\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c276.",
        "Hall, R. E., and C. I. Jones (2007): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Value of Life and the Rise in Health Spending,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics, 122, 39\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c72.",
        "Hult, K. J., and T. J. Philipson (2012): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Public Liabilities and Health Care Policy,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper, National Bureau of Economic Research 18571.",
        "Jones, C. I. (2011): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Life and Growth,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, Stanford University.",
        "Kahneman, D., and A. Tversky (1979): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Prospect Theory: An Analysis of Decisions under Risk,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Econometrica, 47(2), 263\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c292.",
        "Kelly, B. T., L. Pastor, and P. Veronesi (2014): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Price of Political Uncertainty: Theory and Evidence from the Option Market,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, University of Chicago.",
        "Kogan, S., D. Levin, B. Routledge, J. Sagi, and N. Smith (2009): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Predicting Risk from Financial Reports with Regression,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Proceedings of the North American Association for Computational Linguistics Human Language Technologies Conference.",
        "Koijen, R. S., H. Lustig, and S. Van Nieuwerburgh (2012): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Cross-Section and Time Series of Stock and Bond Returns,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper.",
        "Koijen, R. S., T. J. Moskowitz, L. H. Pedersen, and E. B. Vrugt (2013): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Carry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, London Business School.",
        "Koijen, R. S., S. Van Nieuwerburgh, and M. Yogo (2011): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health and Mortality Delta: Assessing the Welfare Cost of Household Insurance Choice,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, University of Chicago.",
        "Landoni, M., and R. Sastry (2013): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Quantifying Tail Risk in Hedge Funds,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper, Columbia Business School.",
        "Lettau, M., and J. A. Wachter (2007): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Why is Long-Horizon Equity Less Risky? A DurationBased Explanation of the Value Premium,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Finance, 62, 55\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c92.",
        "Loughran, T., and B. McDonald (2011): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093When is a Liability not a Liability? Textual Analysis, Dictionaries, and 10-Ks,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Finance, 66, 35\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c65.",
        "Lucas, D. e. (2010): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Measuring and Managing Federal Financial Risk,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Chicago: University of Chicago Press.",
        "McGrattan, E. R., and E. C. Prescott (2003): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Average Debt and Equity Returns: Puzzling ?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, AEA Papers and Proceedings, 93(2), 392\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c397.",
        "Newhouse, J. P. (1992): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Medical Care Costs: How Much Welfare Loss?,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Economic Perspectives, 6, 3\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c21.",
        "Pastor, L., and P. Veronesi (2011): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Political Uncertainty and Risk Premia,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working Paper.",
        "(2012): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Uncertainty About Government Policy and Stock Prices,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Finance, forthcoming.",
        "PhRMA (2013): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Biopharmaceutical Research Industry Profile,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d .",
        "Robbins, C., O. Belay, M. Donahoe, and J. Lee (2012): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Industry-level Output Price Indexes for R&D: An Input-cost Approach with R&D Productivity Adjustment,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Working paper, Bureau of Economic Analysis Paper 0090.",
        "Sala-i-Martin, X. X., G. Doppelhofer, and R. I. Miller (2004): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Determinants of LongTerm Growth: A Bayesian Averaging of Classical Estimates (BACE) Approach,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 94, 813\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c835.",
        "Sharpe, W. (1964): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Capital Asset Prices: A Theory of Market Equilibrium under Conditions of Risk,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Finance, 19, 425\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c444.",
        "Viscusi, K. W., and W. N. Evans (1990): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Utility Functions that Depend on Health Status: Estimates and Economic Implications,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Economic Review, 80, 353\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c374.",
        "Yogo, M. (2006): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A Consumption-Based Explanation of the Cross Section of Expected Stock Returns,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Finance, 61(2), 539\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c580.",
        "Zhang, L. (2005): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Value Premium,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Finance, 60, 67\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c103. Panel A: Industry alphas relative to the CAPM and the Fama and French model Consumer goods Manufacturing HiTec Health Other Medical equipment Drugs CAPM 1.81 1.66-0.83 3.31 0.22 3.71 3.70 T-statistic 1.40 1.54-0.54 1.61 0.17 1.40 1.78 Fama and French-0.13 1.04 1.67 5.01-2.66 6.44 5.37 T-statistic-0.09 0.84 0.86 2.44-2.75 2.05 2.63 No. of observations 52 52 52 52 52 52 52 Panel B: Industry alphas relative to models extended with the health care factor Medical equipment Drugs CAPM + HC factor 0.22 0.31 T-statistic 0.14 0.71 FF+ HC factor 0.81 0.37 T-statistic 0.47 0.70 No. of observations 52 52"
    ]
}